Condition 1: breast cancer. Condition 2: heart failure. Breast, unspecified Congestive heart failure
Conditions
Interventions
Intervention 1: Carvedilol tab 12.5 mg daily for 5 months during chemotherapy. Intervention 2: placebo tab daily for 5 months during chemotherapy.
Treatment - Drugs
Carvedilol tab 12.5 mg daily for 5 months during chemotherapy
placebo tab daily for 5 months during chemotherapy
Sponsors
Vice chancellor for research, Mashhad University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
No minimum to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: breast cancer patients who are candidate for chemotherapy with adriamycin. Exclusion criteria: documented heart disease; history of radiation or chemotherapy for cancer; metastatic disease; atrial fibrillation; BMI more than 30; creatinin more than 2; EF less than 30%; pulmonary congestion; beta blocker contraindications; insulin dependent diabetes mellitus; major depression; suicide attempt; pregnancy
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Strain rate. Timepoint: before intervention, at the middle of intervention, after intervention. Method of measurement: echocardiography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Complications of carvedilol. Timepoint: during intervention. Method of measurement: by taking history. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAhmad Tashakori Beheshti
cardiovascular research center, mashhad university of medical sceinces
Outcome results
None listed